Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02129322 | Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1 | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Feb 15, 2021 | clinicaltrials |
| NCT03688568 | Study of Imatinib in Children With Neurofibromatosis and Airway Tumors | withdrawn | Phase 2 | 0 | Indiana UniversityOTHER | 1 | Feb 12, 2021 | clinicaltrials |
| NCT04267237 |
| withdrawn |
| Phase 2 |
| 0 |
| Hoffmann-La RocheINDUSTRY |
| 0 |
| Feb 4, 2021 |
| clinicaltrials |
| NCT04398927 | Systemic Chemotherapy Plus PD-1 for Metastasis ICC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04186156 | A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer | withdrawn | Phase 2 | 0 | Karus Therapeutics LimitedINDUSTRY | 1 | Feb 3, 2021 | clinicaltrials |
| NCT03515707 | Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT03901378 | Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma | withdrawn | Phase 2 | 0 | Ochsner Health SystemOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT04585932 | Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT04373083 | Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma | withdrawn | Phase 2 | 0 | Regeneron PharmaceuticalsINDUSTRY | 0 | Jan 15, 2021 | clinicaltrials |
| NCT02336984 | A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS | withdrawn | Phase 1 / Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 11, 2021 | clinicaltrials |
| NCT03719898 | Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma | withdrawn | Phase 2 | 0 | Fox Chase Cancer CenterOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT03739606 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | Dec 17, 2020 | clinicaltrials |
| NCT04437953 | Avatrombopag for Thrombocytopenia in People With Cancer | withdrawn | Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Dec 8, 2020 | clinicaltrials |
| NCT04460729 | A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Dec 3, 2020 | clinicaltrials |
| NCT03361319 | Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma(N3) | withdrawn | Phase 1 / Phase 2 | 0 | Royal Marsden NHS Foundation TrustOTHER | 0 | Nov 24, 2020 | clinicaltrials |
| NCT01097239 | Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Imperial College LondonOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT04267913 | Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial) | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 0 | Nov 20, 2020 | clinicaltrials |
| NCT04262375 | A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION(DOMINATION) | withdrawn | Phase 2 | 0 | University Health Network, TorontoOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT02109653 | Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC | withdrawn | Phase 2 | 0 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04493099 | Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT03699033 | Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Stephanie SmiddyOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT04197219 | Pembrolizumab With Axitinib in Recurrent Endometrial Cancer | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Nov 5, 2020 | clinicaltrials |
| NCT04231864 | Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer | withdrawn | Phase 2 | 0 | Alain AlgaziOTHER | 0 | Oct 26, 2020 | clinicaltrials |
| NCT03484962 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03501056 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03509298 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03524261 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03524274 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03540199 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03553914 | PLM60 for Peripheral T Cell Lymphoma (PTCL) | withdrawn | Phase 1 / Phase 2 | 0 | Conjupro Biotherapeutics, Inc.INDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03554395 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03972046 | Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma | withdrawn | Phase 2 | 0 | TriHealth Inc.OTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04116359 | Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Sep 28, 2020 | clinicaltrials |
| NCT04220476 | CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer(CIMER) | withdrawn | Phase 2 | 0 | Weill Medical College of Cornell UniversityOTHER | 0 | Sep 21, 2020 | clinicaltrials |
| NCT00226746 | Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer | withdrawn | Phase 2 | 0 | New York Presbyterian Brooklyn Methodist HospitalOTHER | 1 | Sep 18, 2020 | clinicaltrials |
| NCT03348826 | Study of Sodium Bicarbonate in Restoring Blocked Catheters | withdrawn | Phase 2 | 0 | University Health Network, TorontoOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT03038477 | A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection | withdrawn | Phase 2 | 0 | University of Colorado, DenverOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT03628144 | Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT03506139 | Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma | withdrawn | Phase 2 | 0 | John M. BuattiOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04058145 | AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | Sep 7, 2020 | clinicaltrials |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 7, 2020 | clinicaltrials |
| NCT04093115 | Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma(HNSCC) | withdrawn | Phase 2 | 0 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 3, 2020 | clinicaltrials |
| NCT01460602 | Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Louisiana State University Health Sciences Center ShreveportOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT01079793 | Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery | withdrawn | Phase 1 / Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT01302613 | Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma | withdrawn | Phase 1 / Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT01818999 | Ixabepilone and SBRT For Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT03126461 | SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Feb 15, 2021source: clinicaltrials